Condition
Locally Recurrent Cancer
Total Trials
2
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 1 (2)
Trial Status
Active Not Recruiting1
Withdrawn1
Clinical Trials (2)
Showing 2 of 2 trials
NCT03813394Phase 1Active Not RecruitingPrimary
Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC
NCT04332549Phase 1Withdrawn
To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With Locally Recurrent or Metastatic Breast Cancer
Showing all 2 trials